CAP TODAY/AstraZeneca Webinar: Diving Deeper into the HER2 IHC Spectrum: Evolving Viewpoints and an Emerging Digital Landscape

Thank you

This live web event has ended. Thank you for attending.

Description

Diving Deeper into the HER2 IHC Spectrum:
Evolving Viewpoints and an Emerging Digital Landscape

Why should you register now for this webinar?
In this session, Dr. Savitri Krishnamurthy will take a deep dive into the HER2
IHC spectrum, exploring the latest advancements and their implications in
breast cancer diagnostics. Key topics include:

Identifying HER2-low status in breast cancer—a review of the 2023 ASCO-CAP guidelines for HER2 testing in breast cancer, bringing awareness to recommendations around reporting HER2 IHC 1+, IHC 2+/ISH- results, and best practices for differentiating HER2 IHC 1+ and 0 tumors
Emerging digital pathology and computational image analysis technologies for HER2 evaluation—an overview of recent advancements in this field, focusing on how technology may be used as a partner for HER2 IHC assessment in breast cancer

Brought to you by CAP TODAY
Moderated by Bob McGonnagle, Publisher, CAP TODAY
Presenter: Savitri Krishnamurthy, MD
You will have the opportunity to ask questions of our distinguished presenter

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc, and AstraZeneca. The speaker is being compensated for the presentation. This program is not CME accredited and may not be used for CME accreditation. ©2023 Daiichi Sankyo, Inc. and AstraZeneca. PP-US-8201a-1774 09/23

Contributors

Bob McGonnagle

Publisher, CAP TODAY
Savitri Krishnamurthy, MD

Professor, Department of Pathology,
Division of Pathology and Laboratory Medicine
The University of Texas MD Anderson Cancer Center, Houston, Texas